Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia - Test2 - elhamkhani - TriplyDB

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

http://www.wikidata.org/entity/Q29614280

about

Evolutionary dynamics of cancer in response to targeted combination therapy Expression of the leukemic prognostic marker CD7 is linked to epigenetic modifications in chronic myeloid leukemia Imatinib for treating newly diagnosed chronic myeloid leukemia patients Imatinib for treating patients with chronic myelogeneous leukemia From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance Transcriptome sequencing to detect gene fusions in cancer Selectivity and therapeutic inhibition of kinases: to be or not to be?Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders Structural reengineering of imatinib to decrease cardiac risk in cancer therapy Aberrant Wnt Signaling in Leukemia Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives New Developments in Chronic Myeloid Leukemia: Implications for Therapy Chronic myeloid leukemia: reminiscences and dreams European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib Oncogenic kinase fusions: an evolving arena with innovative clinical opportunities Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia Oral targeted therapy for cancer Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review Tailoring the Treatment of Melanoma: Implications for Personalized Medicine The influence of subclonal resistance mutations on targeted cancer therapy Eosinophilia in Hematologic Disorders New and emerging factors in tumorigenesis: an overview Pharmacology and rationale for imatinib in the treatment of scleroderma Universes collide: combining immunotherapy with targeted therapy for cancer Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells Ten things you should know about protein kinases: IUPHAR Review 14 Functional genomics lead to new therapies in follicular lymphoma Mechanisms of epigenetic regulation of leukemia onset and progression Imatinib in chronic myeloid leukemia: an overview Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations Co-development of diagnostic vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting Current status of hematopoietic stem cell transplant in chronic myeloid leukemia Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer

P2860

Q21128788-857EB97B-ACA4-49A4-A326-51D901CAAB53 Q21245701-E6B11170-9C97-492D-96DD-D767A079DC0C Q24186877-91F18114-F36C-45EA-B850-2C8FEA2442A8 Q24241730-9BD040A3-63F8-46A6-9216-37F9B1446F01 Q24605527-645FD2DE-64D7-4DA9-807A-4E74B5043E14 Q24617270-B4AED0DF-2218-4AF6-9A83-0A09589FE7F0 Q24648017-B57EBACE-FB5C-4166-A2D0-E8DA35358B19 Q24653386-26C86942-301D-4C74-A27C-0DBE34206796 Q24656006-F9B88330-1A60-437A-B2B6-221DEDCE9D8D Q24657681-7DB8E4CA-876F-4AA5-8648-CDD65CEF18B1 Q24685557-6AEF3F49-AE97-4BB7-A26A-873874AE0777 Q26738411-54F5A90C-30D3-4578-AF0D-5922B1B7EE32 Q26738514-BABBED5B-34D2-44F4-8C6D-2966D4717567 Q26741009-E3B6C347-2226-4C03-8181-3A91E4A60134 Q26745669-689E09BF-14AA-41B5-97BD-F5BFB3EBA937 Q26748769-B341CDEF-7BBB-40CB-9406-F9EF4292AE97 Q26749324-5CD54D51-8273-4237-9201-19049E0A2391 Q26751285-CF2A7938-DB82-42C6-AA7E-4529629F786B Q26768158-2E7F7E46-87B9-42D4-8C50-872D9464A562 Q26768600-E564324F-B94D-4DA4-9DAE-1A786682C09F Q26773240-5D627CBE-C5D4-4A18-A704-F3430DB39084 Q26774625-B7251C3D-3B27-40D5-A47F-912EBB301856 Q26775622-4B6EC812-E044-4EA9-9621-7E4564E95883 Q26775806-18B431AB-38B7-42BD-815B-46C3ED98D530 Q26781693-2E946D01-35B5-41CB-93F2-A3C36752E214 Q26799611-50B59724-179E-4147-837B-72559CEDF14A Q26801253-82505EE6-DB35-465D-B19F-BAAB37126DC4 Q26825153-2B626661-5ABD-4B19-8652-60A1D21D13B2 Q26825316-A984CFFA-602B-405F-A7C1-574B1C2C5B7C Q26828528-DCF5D01B-C6C4-4205-B54A-69BDBDF1DC44 Q26849417-03821300-4752-4DD3-B80E-27E13E5A2BA0 Q26852415-84A94DA3-19F9-445F-91D8-832FAAEA092A Q26861785-22E01E4A-8D16-431E-90FB-ADBCFFE22725 Q26865086-DBE46EE7-E988-4D1C-824E-E0B1E274CDAA Q26992272-B2E80FDD-8097-4E19-9A3F-F97DC2972D5C Q27004032-45BE9455-2C77-413C-A1DD-833EB0708747 Q27005742-49C7F1A3-D977-4C1D-A95C-94F5CEE34C6F Q27008389-B43AF2F2-4EE6-4B8B-AE84-49AA8BFAD7B3 Q27010475-C2E8CD14-935F-4B49-9F1A-5A75C3F38491 Q27024235-9A6E8F25-93FD-413B-A940-737B5F3BD851

P2860

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

http://www.wikidata.org/entity/Q29614280

description

2006 nî lūn-bûn

@nan

2006 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

@ast

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

@en

type

label

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

@ast

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

@en

prefLabel

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

@ast

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

@en

P1433

Q29614280-6735C051-7A26-45A0-98BE-D28E76AEB7AD

P1476

Q29614280-CCBB9FBA-3302-4B5B-BD0B-8C177AA479F7

P2093

Q29614280-10239F5E-9B0D-4379-9FA6-643DE0A1C992

Q29614280-23145486-0CF6-4D55-A508-0904D01120DF

Q29614280-283A7ED6-4ACD-41C3-94B2-78B1E986E452

Q29614280-2BF5AC44-EF3D-4456-8804-1A7302135F25

Q29614280-385DCF75-A925-4781-A870-597CE9C757D3

Q29614280-41D711E0-9EAC-4E69-B8B5-8735B2D2CECA

Q29614280-464F9900-D5C6-431F-9EF1-297D545AE348

Q29614280-4999F86D-DBDC-4D32-A83B-35A65FFA0588

Q29614280-5910FBE1-C7E2-4B3C-A80F-FED8C4E325C8

Q29614280-63535C4D-4388-4933-992E-8E924C4E0070

P304

Q29614280-35444DE8-CCD9-4945-878B-D350DC61B036

P31

Q29614280-14346185-0D88-45AD-AD34-7E4F94CD1D2F

P3181

Q29614280-8C4A6828-2D5B-467C-A8A6-2ABB3A292791

P356

Q29614280-72093D3F-39DD-412E-8A72-E7692059D731

P407

Q29614280-44DD17BE-6B6F-4F8A-8BEE-562AB396C618

P433

Q29614280-760A55A4-9B73-4C6B-B8A7-C9CBCBBDDC80

P478

Q29614280-C082FB42-C49C-414B-B686-C10329BFE91C

P50

Q29614280-1E5DC076-6FF8-43B8-A157-453043C27760

Q29614280-75AD30BA-D1A4-4DAC-9588-DFAABF47582F

Q29614280-9B5A51A7-8906-4014-8767-757D5BB0A3F2

Q29614280-C4FE1A5C-3182-4E33-9F23-A8CE10BC9F67

Q29614280-D84EE0FC-73D6-4968-AEAC-A03A7FB2750B

Q29614280-FEB445E6-24CC-4025-8138-E007ABB4DE94

P577

Q29614280-67301D69-98E9-4DE3-A918-2D863067EB60

P698

Q29614280-CE47F279-56C7-41AE-9F5A-25D50AA4DE55

P921

Q29614280-0751FA41-48A7-4418-9160-10A047809F0A

Q29614280-DBAF6E94-CD28-46EC-83DF-E0D3A429AFEA

P3181

P356

P1433

The New England Journal of Medicine

P1476

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

@en

P2093

Bayard L Powell

http://www.w3.org/2001/XMLSchema#string

Bengt Simonsson

http://www.w3.org/2001/XMLSchema#string

Charlene So

http://www.w3.org/2001/XMLSchema#string

Francisco Cervantes

http://www.w3.org/2001/XMLSchema#string

Gregor Verhoef

http://www.w3.org/2001/XMLSchema#string

Hagop Kantarjian

http://www.w3.org/2001/XMLSchema#string

Hermine Agis

http://www.w3.org/2001/XMLSchema#string

IRIS Investigators

http://www.w3.org/2001/XMLSchema#string

Insa Gathmann

http://www.w3.org/2001/XMLSchema#string

Jan J Cornelissen

http://www.w3.org/2001/XMLSchema#string

P304

2408-2417

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

648086

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA062867

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

355

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Hochhaus

Brian J. Druker

Richard A. Larson

Giuseppe Saglio

François Guilhot

P577

2006-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17151364

http://www.w3.org/2001/XMLSchema#string

P921

chronic myeloid leukemia